Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 28 October 2020, 09:07 HKT/SGT
Share:
    

Source: Eisai
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 13th Clinical Trials on Alzheimer's Disease Conference

TOKYO, Oct 28, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct a total of 7 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (Development Code: BAN2401), at the 13th Clinical Trials on Alzheimer's Disease (CTAD) conference to be held virtually from November 4 to 7, 2020.

Regarding lecanemab, Eisai will conduct four oral presentations. The first oral presentation will cover clinical study design and initial screening results of the newly initiated Phase III clinical study AHEAD 3-45 for preclinical Alzheimer's disease (AD) patients. The second oral presentation will cover the latest analysis results on expression of amyloid-related imaging abnormalities-edema (ARIA-E) from the Phase II study (Study 201) conducted on early AD patients. The third oral presentation will cover changes in brain-Abeta amounts and preliminary analysis results on ARIA-E expression as observed in the first 12-month treatment period of the ongoing open-label extension (OLE) study of Study 201. The fourth oral presentation will cover baseline characteristics of currently enrolled subjects in the Phase III study Clarity AD being conducted on early AD patients.

Other presentation topics include the effectiveness of lemborexant on irregular-sleep-wake- rhythm-disorder (ISWRD) in AD as observed in mouse models in relation to clinical trials, as well results from a Phase I, First-In-Human (FIH), Single Ascending Dose (SAD) study of the novel anti-microtubule binding region (MTBR) tau antibody E2814.

Regarding aducanumab, Biogen Inc. (Headquarters: Cambridge, Massachusetts, United States) will conduct an oral presentation on the design of its Phase IIIb redosing study EMBARK. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), for approval of aducanumab as an AD treatment, was accepted and received priority review designation in August 2020.

Lecanemab and aducanumab are being jointly developed by Eisai and Biogen Inc.

Regarding the joint research effort with Sysmex Corporation for creation of simplified diagnosis of AD using blood, a poster will be presented on prediction of Amyloid Positivity Defined by Amyloid PET Centiloid through Plasma Aβ Ratio Measurement on a Fully Automated Immunoassay, HISCLTM*.

Eisai aims to realize the prevention and cure of dementia through a multi-dimensional and holistic approach with a foundation of over 35 years of experience of drug discovery activities in the area of AD and dementia. Eisai strives to create innovative medicines as soon as possible to further contribute to addressing the unmet medical needs of, as well as increasing the benefits provided to, those living with the disease and their families.

*HISCLTM is a trademark of Sysmex Corporation.


Contact:
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Apr 18, 2025 15:52 HKT/SGT
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
Apr 1, 2025 12:15 HKT/SGT
Eisai to Divest Rights for Pariet in China to Peak Pharma
Mar 25, 2025 16:28 HKT/SGT
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
Mar 25, 2025 11:21 HKT/SGT
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
Mar 10, 2025 19:24 HKT/SGT
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
Mar 5, 2025 08:09 HKT/SGT
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
Mar 4, 2025 16:22 HKT/SGT
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Mar 3, 2025 14:41 HKT/SGT
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
Mar 3, 2025 12:53 HKT/SGT
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
Feb 28, 2025 11:31 HKT/SGT
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: